| P50 | author | Francesco Bertolini | Q56850281 |
| P2093 | author name string | Gauthier Bouche | |
| | Vikas P Sukhatme | |
| P2860 | cites work | Cancer genome landscapes | Q22242276 |
| | Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer | Q24201720 |
| | Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide | Q24614147 |
| | Predicting new molecular targets for known drugs | Q24649687 |
| | Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs | Q27694755 |
| | Improved overall survival in melanoma with combined dabrafenib and trametinib | Q27853091 |
| | Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 |
| | A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer | Q28195274 |
| | Metformin in breast cancer: time for action | Q28247070 |
| | Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival | Q28277824 |
| | Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer | Q28299100 |
| | Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial | Q28361953 |
| | Prediction of drug-target interactions and drug repositioning via network-based inference | Q28483634 |
| | The Connectivity Map: a new tool for biomedical research | Q28530408 |
| | Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity | Q28541594 |
| | Drug repositioning: identifying and developing new uses for existing drugs | Q29614779 |
| | Drug target identification using side-effect similarity | Q29615103 |
| | A new initiative on precision medicine | Q29615654 |
| | Metformin and reduced risk of cancer in diabetic patients | Q29616275 |
| | Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs | Q31129007 |
| | A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial | Q33166212 |
| | The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma | Q33342020 |
| | Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors | Q33344650 |
| | Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma | Q33344746 |
| | Rational design of indoleamine 2,3-dioxygenase inhibitors | Q33522429 |
| | Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines | Q33611069 |
| | Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD) | Q33648694 |
| | Aspirin use and survival after diagnosis of colorectal cancer | Q33764480 |
| | Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials | Q33767211 |
| | Exploiting the critical perioperative period to improve long-term cancer outcomes | Q33871661 |
| | Computational repositioning and preclinical validation of pentamidine for renal cell cancer. | Q33875574 |
| | Antitumor activity of thalidomide in refractory multiple myeloma | Q33880642 |
| | The Repurposing Drugs in Oncology (ReDO) Project. | Q33893949 |
| | Comparative Effectiveness Questions in Oncology | Q57765770 |
| | Antitumour immunity gets a boost | Q59092145 |
| | Treatment With β-Blockers and Reduced Disease Progression in Patients With Thick Melanoma | Q59489502 |
| | Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival | Q64018888 |
| | Verapamil increases the survival of patients with anthracycline-resistant metastatic breast carcinoma | Q73356015 |
| | Perioperative desmopressin prolongs survival in surgically treated bitches with mammary gland tumours: a pilot study | Q80844510 |
| | Nonprofit drug companies | Q81472103 |
| | Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia | Q83203054 |
| | Plerixafor | Q83265740 |
| | Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India | Q83368779 |
| | Daily aspirin use and cancer mortality in a large US cohort | Q84783537 |
| | Drug development costs jump to $2.6 billion | Q86678318 |
| | Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme | Q41943380 |
| | DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information. | Q41979190 |
| | Discovery and exploitation of novel targets by approved drugs | Q42453604 |
| | Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantatio | Q43282877 |
| | Thalidomide and dexamethasone combination for refractory multiple myeloma | Q43719056 |
| | Randomized, double-blind phase II study to compare nitroglycerin plus oral vinorelbine plus cisplatin with oral vinorelbine plus cisplatin alone in patients with stage IIIB/IV non-small cell lung cancer (NSCLC). | Q43900248 |
| | Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications | Q44010411 |
| | Thalidomide and dexamethasone for resistant multiple myeloma | Q44461621 |
| | In silico drug repositioning: what we need to know | Q44525419 |
| | Drug repositioning from bench to bedside: tumour remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer | Q44581875 |
| | The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. | Q44658657 |
| | Complementary populations of human adipose CD34+ progenitor cells promote growth, angiogenesis, and metastasis of breast cancer. | Q44778368 |
| | A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer | Q45013436 |
| | Use of crowdsourcing for cancer clinical trial development. | Q45949689 |
| | Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma | Q46052750 |
| | Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. | Q46124744 |
| | Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas | Q46270898 |
| | Oxymoron no more: the potential of nonprofit drug companies to deliver on the promise of medicines for the developing world | Q46449781 |
| | Propranolol for severe hemangiomas of infancy. | Q46542573 |
| | Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer | Q46919114 |
| | The major role of clinicians in the discovery of off-label drug therapies | Q46964969 |
| | In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. | Q48494604 |
| | Security and maximal tolerated doses of fluvastatin in pediatric cancer patients | Q48760131 |
| | Rare cancers are not so rare: the rare cancer burden in Europe. | Q51171868 |
| | A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†. | Q51597242 |
| | Intratumor heterogeneity: seeing the wood for the trees. | Q53097757 |
| | Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists. | Q53359638 |
| | Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma. | Q53482041 |
| | Retinoic acid treatment of acute promyelocytic leukemia: in vitro and in vivo observations. | Q53556858 |
| | Significant Survival Benefit to Patients with Advanced Non-Small-Cell Lung Cancer from Treatment with Clarithromycin | Q53967667 |
| | Drug discovery. Repurposing with a difference. | Q55051971 |
| | Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells | Q33971668 |
| | Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial | Q33993957 |
| | Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing | Q34101536 |
| | The sympathetic nervous system induces a metastatic switch in primary breast cancer | Q34134468 |
| | Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders | Q34135248 |
| | A review of the history, properties, and use of the immunomodulatory compound lenalidomide. | Q34173071 |
| | The effectiveness of propranolol in treating infantile haemangiomas: a meta-analysis including 35 studies | Q34209504 |
| | Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials | Q34263106 |
| | Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia | Q34314927 |
| | Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer | Q34336386 |
| | Multiple myeloma. | Q34362643 |
| | Multicomponent therapeutics for networked systems | Q34390417 |
| | Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. | Q34412152 |
| | Phenotypic screening in cancer drug discovery - past, present and future | Q34429484 |
| | Estimates of benefits and harms of prophylactic use of aspirin in the general population | Q34432503 |
| | Metformin--mode of action and clinical implications for diabetes and cancer | Q34658712 |
| | Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study | Q34729804 |
| | Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma. | Q35002582 |
| | Metformin use and lung cancer risk in patients with diabetes. | Q35046673 |
| | Immune-mediated antitumor effect by type 2 diabetes drug, metformin | Q35089957 |
| | Systematic discovery of multicomponent therapeutics | Q35147474 |
| | The bicyclam AMD3100 story | Q35158014 |
| | Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants | Q35246178 |
| | Treatment of plasma cell dyscrasias with thalidomide and its derivatives | Q35596473 |
| | Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival | Q35640094 |
| | Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment | Q35640172 |
| | Chronic stress enhances progression of acute lymphoblastic leukemia via β-adrenergic signaling. | Q35877948 |
| | Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership | Q35927074 |
| | New sources of drugs for hematologic malignancies | Q35979113 |
| | Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial | Q36303184 |
| | Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth | Q36545664 |
| | Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. | Q36554423 |
| | The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development | Q36612613 |
| | Primary extraosseous Ewing sarcoma of the lung in children | Q36791086 |
| | Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications | Q36897767 |
| | β-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. | Q36959073 |
| | Unfinished business: target-based drug discovery | Q37025606 |
| | Aspirin use and risk of colorectal cancer according to BRAF mutation status | Q37094281 |
| | Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia | Q37172988 |
| | A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. | Q37395737 |
| | Mining for therapeutic gold | Q37403312 |
| | Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis | Q37404368 |
| | Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study | Q37412290 |
| | Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma | Q37485279 |
| | Successful applications of computer aided drug discovery: moving drugs from concept to the clinic | Q37636258 |
| | Drug repurposing in pediatrics and pediatric hematology oncology | Q38029825 |
| | Predictive methods in drug repurposing: gold mine or just a bigger haystack? | Q38070040 |
| | Has the time come for metronomics in low-income and middle-income countries? | Q38103647 |
| | One hundred thousand mouse clicks down the road: selected online resources supporting drug discovery collected over a decade | Q38119805 |
| | Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates | Q38147841 |
| | Unlocking the potential of retinoic acid in anticancer therapy | Q38269931 |
| | The anatomy of medical research: US and international comparisons | Q38317057 |
| | Adjuvant therapy with bemiparin in patients with limited-stage small cell lung cancer: results from the ABEL study | Q38436991 |
| | The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells | Q38959006 |
| | Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial | Q38996447 |
| | More multiarm randomised trials of superiority are needed | Q39339808 |
| | Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. | Q39340562 |
| | Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening | Q39369674 |
| | A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer | Q39458300 |
| | Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor | Q39745162 |
| | Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors | Q39988198 |
| | Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia | Q40640442 |
| | Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent | Q41327770 |
| | Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent | Q41668110 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 732-742 | |
| P577 | publication date | 2015-10-20 | |
| P1433 | published in | Nature Reviews Clinical Oncology | Q641640 |
| P1476 | title | Drug repurposing in oncology--patient and health systems opportunities | |
| P478 | volume | 12 | |